NORA-520
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NORA-520, also known as NRT-023, is a prodrug of brexanolone (allopregnanolone) and hence GABA A receptor positive allosteric modulator which is under development for the treatment of postpartum depression, major depressive disorder, essential tremor, bipolar disorder, epilepsy, and generalized anxiety disorder. In contrast to brexanolone itself, which must be used parenterally via intravenous infusion, NORA-520 is active and used via oral administration. The drug is under development by Gerbera Therapeutics. As of December 2025, it is in phase 2 clinical trials for postpartum depression, the preclinical research stage of development for major depressive disorder and essential tremor, and the research stage of development for bipolar disorder, epilepsy, and generalized anxiety disorder.
NORA-520, also known as NRT-023, is a prodrug of brexanolone (allopregnanolone) and hence GABA A receptor positive allosteric modulator which is under development for the treatment of postpartum depression, major depressive disorder, essential tremor, bipolar disorder, epilepsy, and generalized anxiety disorder. In contrast to brexanolone itself, which must be used parenterally via intravenous infusion, NORA-520 is active and used via oral administration. The drug is under development by Gerbera Therapeutics. As of December 2025, it is in phase 2 clinical trials for postpartum depression, the preclinical research stage of development for major depressive disorder and essential tremor, and the research stage of development for bipolar disorder, epilepsy, and generalized anxiety disorder.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372024020 under CC BY-SA 4.0; modifications have been made.